A detailed history of Bellevue Group Ag transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Bellevue Group Ag holds 4,839,779 shares of FATE stock, worth $11.1 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
4,839,779
Previous 4,839,779 -0.0%
Holding current value
$11.1 Million
Previous $15.9 Million 6.71%
% of portfolio
0.29%
Previous 0.27%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$3.54 - $8.35 $41,772 - $98,530
-11,800 Reduced 0.24%
4,839,779 $35.5 Million
Q3 2023

Nov 14, 2023

SELL
$2.02 - $5.04 $8,484 - $21,168
-4,200 Reduced 0.09%
4,851,579 $10.3 Million
Q1 2023

May 15, 2023

SELL
$4.24 - $11.12 $23,320 - $61,159
-5,500 Reduced 0.11%
4,855,779 $27.7 Million
Q4 2022

Feb 14, 2023

BUY
$9.86 - $23.83 $11 Million - $26.6 Million
1,115,193 Added 29.77%
4,861,279 $49.1 Million
Q3 2022

Nov 14, 2022

BUY
$21.04 - $36.06 $4.12 Million - $7.07 Million
196,000 Added 5.52%
3,746,086 $84 Million
Q2 2022

Aug 11, 2022

SELL
$17.78 - $42.39 $469,392 - $1.12 Million
-26,400 Reduced 0.74%
3,550,086 $88 Million
Q1 2022

May 13, 2022

SELL
$29.67 - $60.28 $5.91 Million - $12 Million
-199,250 Reduced 5.28%
3,576,486 $139 Million
Q4 2021

Feb 10, 2022

BUY
$47.84 - $64.34 $25.7 Million - $34.6 Million
537,700 Added 16.61%
3,775,736 $221 Million
Q3 2021

Nov 12, 2021

BUY
$59.27 - $95.73 $37 Million - $59.8 Million
624,500 Added 23.89%
3,238,036 $192 Million
Q2 2021

Aug 12, 2021

BUY
$67.25 - $92.52 $27.2 Million - $37.4 Million
404,200 Added 18.3%
2,613,536 $227 Million
Q1 2021

May 12, 2021

BUY
$72.16 - $117.4 $7.35 Million - $12 Million
101,836 Added 4.83%
2,209,336 $182 Million
Q4 2020

Feb 16, 2021

SELL
$38.09 - $100.95 $4.19 Million - $11.1 Million
-110,000 Reduced 4.96%
2,107,500 $192 Million
Q3 2020

Nov 16, 2020

BUY
$30.41 - $40.5 $7.79 Million - $10.4 Million
256,100 Added 13.06%
2,217,500 $88.6 Million
Q2 2020

Aug 13, 2020

BUY
$20.21 - $35.23 $8.05 Million - $14 Million
398,200 Added 25.47%
1,961,400 $67.3 Million
Q1 2020

May 14, 2020

BUY
$17.28 - $31.88 $25.6 Million - $47.2 Million
1,480,400 Added 1787.92%
1,563,200 $34.7 Million
Q4 2019

Feb 14, 2020

BUY
$13.39 - $20.73 $303,953 - $470,571
22,700 Added 37.77%
82,800 $1.62 Million
Q3 2019

Nov 14, 2019

BUY
$15.47 - $22.5 $17,017 - $24,750
1,100 Added 1.86%
60,100 $933,000
Q2 2019

Aug 14, 2019

BUY
$15.61 - $20.44 $920,990 - $1.21 Million
59,000 New
59,000 $1.2 Million

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $222M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.